These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 35704157)
1. Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. Weller J; Schäfer N; Schaub C; Potthoff AL; Steinbach JP; Schlegel U; Sabel M; Hau P; Seidel C; Krex D; Goldbrunner R; Pietsch T; Tzaridis T; Zeyen T; Borger V; Güresir E; Vatter H; Herrlinger U; Schneider M J Neurooncol; 2022 Aug; 159(1):95-101. PubMed ID: 35704157 [TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360 [TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
4. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902 [TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. Tzaridis T; Schäfer N; Weller J; Steinbach JP; Schlegel U; Seidel S; Sabel M; Hau P; Seidel C; Krex D; Goldbrunner R; Tonn JC; Grauer O; Kebir S; Schneider M; Schaub C; Vatter H; Coch C; Glas M; Fimmers R; Pietsch T; Reifenberger G; Herrlinger U; Felsberg J Int J Cancer; 2021 Apr; 148(7):1695-1707. PubMed ID: 33113214 [TBL] [Abstract][Full Text] [Related]
7. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820 [TBL] [Abstract][Full Text] [Related]
8. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients? Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743 [TBL] [Abstract][Full Text] [Related]
9. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829 [TBL] [Abstract][Full Text] [Related]
10. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Wick A; Kessler T; Platten M; Meisner C; Bamberg M; Herrlinger U; Felsberg J; Weyerbrock A; Papsdorf K; Steinbach JP; Sabel M; Vesper J; Debus J; Meixensberger J; Ketter R; Hertler C; Mayer-Steinacker R; Weisang S; Bölting H; Reuss D; Reifenberger G; Sahm F; von Deimling A; Weller M; Wick W Neuro Oncol; 2020 Aug; 22(8):1162-1172. PubMed ID: 32064499 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of MGMT promoter methylation on the survival of TMZ treated Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600 [TBL] [Abstract][Full Text] [Related]
15. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343 [TBL] [Abstract][Full Text] [Related]
16. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344 [TBL] [Abstract][Full Text] [Related]
17. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study. Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781 [TBL] [Abstract][Full Text] [Related]
18. Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status. Alafandi A; van Garderen KA; Klein S; van der Voort SR; Rizopoulos D; Nabors L; Stupp R; Weller M; Gorlia T; Tonn JC; Smits M Eur J Cancer; 2023 Jul; 188():122-130. PubMed ID: 37235895 [TBL] [Abstract][Full Text] [Related]
19. Treatment considerations for MGMT-unmethylated glioblastoma. Taylor JW; Schiff D Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859 [TBL] [Abstract][Full Text] [Related]
20. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]